Report : Europe Pharmaceutical Excipients Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product (Organic Chemicals, Inorganic Chemicals, and Other Products); Functionality (Fillers and Diluents, Suspending and Viscosity Agents, Coating Agents, Binders, Preservatives, Emulsifying Agents, and Other Functionalities); Type of Formulation (Oral Formulations, Topical Formulations, Parenteral Formulations, and Other Formulations)
At 6.5% CAGR, the Europe Pharmaceutical Excipients Market is speculated to be worth US$ 4,198.83 million by 2028, says Business Market Insights
According to Business Market Insights’ research, the Europe pharmaceutical excipients market was valued at US$ 2,878.05 million in 2022 and is expected to reach US$ 4,198.83 million by 2028, registering an annual growth rate of 6.5% from 2022 to 2028. Increasing product launches and growing generics are the critical factors attributed to the Europe pharmaceutical excipients market expansion.
The pharmaceutical excipients market is characterized by the presence of large and small market players. A few product launches have taken place in recent years. For instance, in October 2022, Rouqette, a pharmaceutical and nutraceutical excipients provider, launched two next-generation mannitol products—PEARLITOL CR-H and PEARLITOL 200 GT— for direct compression. These excipients have been specially formulated to overcome the unique drug formulation challenges in the pharmaceutical spaces, which helps the manufacturers optimize direct compression processes and expand into application areas such as mini tabs and controlled-release tablets. Similarly, in March 2022, Lubrizol Life Science Health launched Apisolex, a novel solubility-enhancing excipient for parenteral drug products. With the ability to improve solubility by up to 50,000-fold and support high drug loading, Apisolex excipient provides access to new and improved parenteral drug products. This is especially relevant in oncology, as direct injection of drugs into the bloodstream ensures higher bioavailability and lower patient variability compared to oral delivery. The active participation of market players in product innovation and development leading to the increase in product launches fuel the growth of the Europe pharmaceutical excipients market.
On the contrary, cost and time-intensive drug development process hurdles the growth of Europe pharmaceutical excipients market.
Based on type, the Europe pharmaceutical excipients market is segmented into bioresorbable polymers & lipids & liposome-based formulation, oleochemicals, sugars, cellulose, starches, petrochemicals, plant protein & polyols & cyclodextrins, inorganic chemicals, and others. The inorganic chemicals segment held 26.6% market share in 2022, amassing US$ 765.46 million. It is projected to garner US$ 1,084.31 million by 2028 to expand at 6.0% CAGR during 2022–2028.
Based on clinical indication, the Europe pharmaceutical excipients market is segmented into cancer, metabolic, infectious diseases, dental, ophthalmic, gene therapies, and others. The cancer segment held 32.8% market share in 2022, amassing US$ 942.88 million. It is projected to garner US$ 1,345.70 million by 2028 to expand at 6.1% CAGR during 2022–2028.
Based on functionality, the Europe pharmaceutical excipients market is segmented into coloring agent & coating agents, sweetener & flavoring agents, suspending & viscosity agents, preservative & controlled-release, antioxidant & oil, tablet filler & diluents, binders & compression aids & granulating agents, emulsifiers, and others. The tablet filler and diluents segment held 26.0% market share in 2022, amassing US$ 747.40 million. It is projected to garner US$ 1,147.74 million by 2028 to expand at 7.4% CAGR during 2022–2028.
Based on application, the Europe pharmaceutical excipients market is segmented into parenteral, orals formulations & tablets, capsules, liquid & injectable, physicochemical excipient container interactions in prefilled syringes, nutraceuticals & OTC, topical, and others. The orals formulations & tablets segment held 42.7% market share in 2022, amassing US$ 1,230.34 million. It is projected to garner US$ 1,852.30 million by 2028 to expand at 7.1% CAGR during 2022–2028.
Based on end user, the Europe pharmaceutical excipients market is segmented into biopharma industries, pharma industries, animal health, and others. The pharma industries segment held 44.4% market share in 2022, amassing US$ 1,276.54 million. It is projected to garner US$ 1,839.92 million by 2028 to expand at 6.3% CAGR during 2022–2028.
Based on country, the Europe pharmaceutical excipients market is segmented into UK, Germany, France, Italy, Spain, and the Rest of Europe. Our regional analysis states that Germany captured 29.5% market share in 2022. It was assessed at US$ 847.59 million in 2022 and is likely to hit US$ 4,480.20 million by 2028, exhibiting a CAGR of 6.1% during the forecast period.
Key players dominating the Europe pharmaceutical excipients market are Archer-Daniels-Midland Co, AshLand Inc, Avantor Inc, BASF SE, Evonik Industries AG, JRS PHARMA GmbH & Co. KG, MEGGLE GmbH & Co KG, Roquette Freres SA, The Dow Chemical Co, and The Lubrizol Corp among others.
- In 2020, Evonik launched RESOMER Precise platform of custom functional excipients to precisely control the release profile of parenteral drug products.
Contact Person: Sameer Joshi
Phone: +1- 646- 491- 9876
Email id: firstname.lastname@example.org